Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data

BACKGROUND: A significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack of efficacy or safety concerns. Studies of biologic therapy switch regimens in sJIA are required. METHODS: Patients with sJIA wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexeeva, Ekaterina, Krekhova, Elizaveta, Dvoryakovskaya, Tatyana, Isaeva, Ksenia, Chomakhidze, Aleksandra, Chistyakova, Evgeniya, Lomakina, Olga, Denisova, Rina, Mamutova, Anna, Fetisova, Anna, Gautier, Marina, Vankova, Dariya, Kriulin, Ivan, Saygitov, Ruslan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992960/
https://www.ncbi.nlm.nih.gov/pubmed/36911042
http://dx.doi.org/10.3389/fped.2023.1114207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992960/
https://www.ncbi.nlm.nih.gov/pubmed/36911042
http://dx.doi.org/10.3389/fped.2023.1114207

Ejemplares similares